CN1165310C - 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) - Google Patents

含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) Download PDF

Info

Publication number
CN1165310C
CN1165310C CNB008034702A CN00803470A CN1165310C CN 1165310 C CN1165310 C CN 1165310C CN B008034702 A CNB008034702 A CN B008034702A CN 00803470 A CN00803470 A CN 00803470A CN 1165310 C CN1165310 C CN 1165310C
Authority
CN
China
Prior art keywords
drug
inhibitor
agent
isoenzyme
inducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008034702A
Other languages
English (en)
Chinese (zh)
Other versions
CN1338936A (zh
Inventor
A
A·拉扎
J·S·佩尔斯
�������ɭ
H·G·胡钦森
���ڿ���
D·施内克
T·巴巴
A·托赤
Ų�������޹������޹�˾
Y·雅马古赤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
AstraZeneca AB
Original Assignee
Shionogi and Co Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1165310(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Shionogi and Co Ltd, AstraZeneca AB filed Critical Shionogi and Co Ltd
Publication of CN1338936A publication Critical patent/CN1338936A/zh
Application granted granted Critical
Publication of CN1165310C publication Critical patent/CN1165310C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB008034702A 1999-02-06 2000-02-01 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) Expired - Lifetime CN1165310C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GB9902593.4 1999-02-06
GB9921064.3 1999-09-08
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GB9921063.5 1999-09-08

Publications (2)

Publication Number Publication Date
CN1338936A CN1338936A (zh) 2002-03-06
CN1165310C true CN1165310C (zh) 2004-09-08

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008034702A Expired - Lifetime CN1165310C (zh) 1999-02-06 2000-02-01 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)

Country Status (28)

Country Link
US (3) US6982157B1 (cg-RX-API-DMAC7.html)
EP (1) EP1185274B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002536331A (cg-RX-API-DMAC7.html)
KR (2) KR20010101790A (cg-RX-API-DMAC7.html)
CN (1) CN1165310C (cg-RX-API-DMAC7.html)
AR (1) AR029333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE282415T1 (cg-RX-API-DMAC7.html)
AU (1) AU767304B2 (cg-RX-API-DMAC7.html)
BR (1) BR0007999A (cg-RX-API-DMAC7.html)
CA (1) CA2358632C (cg-RX-API-DMAC7.html)
CZ (1) CZ301296B6 (cg-RX-API-DMAC7.html)
DE (1) DE60015965T2 (cg-RX-API-DMAC7.html)
EE (1) EE04929B1 (cg-RX-API-DMAC7.html)
EG (1) EG23858A (cg-RX-API-DMAC7.html)
ES (1) ES2232418T3 (cg-RX-API-DMAC7.html)
GB (1) GB0000710D0 (cg-RX-API-DMAC7.html)
ID (1) ID30485A (cg-RX-API-DMAC7.html)
IL (1) IL144715A0 (cg-RX-API-DMAC7.html)
IS (1) IS2337B (cg-RX-API-DMAC7.html)
MX (1) MXPA01007905A (cg-RX-API-DMAC7.html)
MY (1) MY130606A (cg-RX-API-DMAC7.html)
NO (1) NO320745B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ512982A (cg-RX-API-DMAC7.html)
PL (1) PL198034B1 (cg-RX-API-DMAC7.html)
PT (1) PT1185274E (cg-RX-API-DMAC7.html)
TR (1) TR200102228T2 (cg-RX-API-DMAC7.html)
TW (1) TWI282738B (cg-RX-API-DMAC7.html)
WO (1) WO2000045817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MX2007001553A (es) 2004-08-06 2008-03-07 Transform Pharmaceuticals Inc Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
EP1948600B1 (en) * 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
EA015682B1 (ru) 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2022001178A (es) * 2019-07-31 2022-02-22 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende inhibidores de la hmg-coa reductasa y fenofibrato.
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0521417T3 (da) * 1991-07-02 1995-03-27 Benckiser Gmbh Joh A Sammenklappelig forrådsflaske
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity

Also Published As

Publication number Publication date
BR0007999A (pt) 2001-11-06
PL198034B1 (pl) 2008-05-30
TR200102228T2 (tr) 2002-03-21
KR20060117381A (ko) 2006-11-16
JP2007277267A (ja) 2007-10-25
MY130606A (en) 2007-07-31
NO20013811D0 (no) 2001-08-03
IS2337B (is) 2008-02-15
EE04929B1 (et) 2007-12-17
AR029333A1 (es) 2003-06-25
ID30485A (id) 2001-12-13
IS6009A (is) 2001-07-17
PT1185274E (pt) 2005-03-31
AU767304B2 (en) 2003-11-06
DE60015965D1 (de) 2004-12-23
PL364780A1 (en) 2004-12-13
WO2000045817A1 (en) 2000-08-10
AU2121800A (en) 2000-08-25
US20090042911A1 (en) 2009-02-12
NO320745B1 (no) 2006-01-23
CN1338936A (zh) 2002-03-06
CA2358632A1 (en) 2000-08-10
CA2358632C (en) 2008-10-28
HK1041817A1 (en) 2002-07-26
US20060040969A1 (en) 2006-02-23
MXPA01007905A (es) 2003-06-04
NO20013811L (no) 2001-10-02
IL144715A0 (en) 2002-06-30
EG23858A (en) 2007-11-18
JP2002536331A (ja) 2002-10-29
TWI282738B (en) 2007-06-21
GB0000710D0 (en) 2000-03-08
ATE282415T1 (de) 2004-12-15
DE60015965T2 (de) 2006-01-05
KR20010101790A (ko) 2001-11-14
NZ512982A (en) 2003-08-29
CZ20012844A3 (cs) 2001-11-14
US6982157B1 (en) 2006-01-03
ES2232418T3 (es) 2005-06-01
CZ301296B6 (cs) 2010-01-06
EE200100406A (et) 2002-10-15
EP1185274A1 (en) 2002-03-13
EP1185274B1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
CN1165310C (zh) 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)
CN1211079C (zh) 稳定的缓释口服给药组合物
CN1244801A (zh) 用于糖尿病的磺酰脲类－格列酮类协同联合给药
CN1215338A (zh) 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
CN1087517A (zh) 用于降低高半胱氨酸水平的药物制剂
CN1268054A (zh) 包含氨氯地平和抑制素化合物的联合疗法
CN1658867A (zh) 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
CN1382440A (zh) 用于治疗抑郁症或预防认知功能退化的方法和药盒
CN1557352A (zh) 菊苣水提取物的新用途
CN1294925C (zh) 一种治疗高血压和高血脂的中药及其制备方法
RU2233162C2 (ru) Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
CN1282457C (zh) 治疗高血脂症的组合物
CN1568993A (zh) 治疗高血脂症的组合物
CN1372476A (zh) 药物组合物
CN1323665C (zh) 治疗高血脂症的组合物
CN1692906A (zh) 治疗高血脂症的组合物
CN1692905A (zh) 治疗高血脂症的组合物
HK1041817B (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
CN1646167A (zh) 代谢综合症的治疗
CN1672683A (zh) 治疗高血脂症的组合物
ZA200105838B (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.
CN1903364A (zh) 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
HK1024180A (en) Sulfonylurea-glitazone synergistic combinations for diabetes
CN1835959A (zh) 用选择性雄激素受体调节剂治疗骨相关病症
CN1701794A (zh) 治疗高血脂症的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040908

CX01 Expiry of patent term